Dashboard
Manage Tickers

BIIB


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bernstein-maintains-market-perform-on-biogen-raises-price-target-to-157
Bernstein Maintains Market Perform on Biog...
11/03/2025 12:49:03

Bernstein analyst William Pickering maintains Biogen (NASDAQ:BIIB) with a Market Perform and raises the price target from $1...

biogen-to-highlight-translational-rnaseq-findings-and-preservation-of-humoral-immunity-in-felzartamab-treated-iga-nephropathy-patients
Biogen To Highlight Translational RNAseq F...
11/03/2025 12:38:19

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights int...

rbc-capital-maintains-outperform-on-biogen-lowers-price-target-to-210
RBC Capital Maintains Outperform on Biogen...
10/31/2025 14:33:39

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $217 to...

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

biogen-lowers-fy2025-adj-eps-guidance-from-1550-1600-to-1450-1500-vs-1580-est-sees-sales-9676b-9773b-vs-9686b-est
Biogen Lowers FY2025 Adj EPS Guidance from...
10/30/2025 11:06:18

Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. sees sales ...

biogen-lowers-fy2025-adj-eps-guidance-from-1550-1600-to-1450-1500-vs-1580-est
Biogen Lowers FY2025 Adj EPS Guidance from...
10/30/2025 10:53:34

Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. Increased e...

biogen-q3-adj-eps-481-beats-388-estimate-sales-2534b-beat-2339b-estimate
Biogen Q3 Adj. EPS $4.81 Beats $3.88 Estim...
10/30/2025 10:52:27

Biogen (NASDAQ:BIIB) reported quarterly earnings of $4.81 per share which beat the analyst consensus estimate of $3.88 by 23.91...

examining-the-future-biogens-earnings-outlook
Examining the Future: Biogen's Earnings Ou...
10/29/2025 17:02:03

Core News & Articles
Reported Sunday, Eisai and Biogen Receive ...
10/27/2025 06:22:40

biogens-immunology-pipeline-has-long-term-potential-analyst
Biogen's Immunology Pipeline Has Long-Term...
10/24/2025 16:47:04

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across mul...

biogen-and-vanqua-bio-announce-agreement-granting-biogen-exclusive-worldwide-rights-to-vanquas-c5ar1-antagonist-vanqua-to-receive-70m-upfront-and-up-to-990m-in-miletones
Biogen And Vanqua Bio Announce Agreement G...
10/24/2025 11:32:46

biogen-to-present-data-from-trials-evaluating-dapirolizumab-pegol-at-american-college-of-rheumatology-convergence-2025-in-chicago
Biogen To Present Data From Trials Evaluat...
10/22/2025 11:37:56

Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc...

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity
Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

biogen-says-estimated-charge-expected-to-impact-gaap--non-gaap-net-income-per-diluted-share-for-q3-by-001-per-share-expects-q3-results-to-include-acquired-in-process-rd-upfront-and-milestone-expense-of-about-2m-on-pre-tax-basis
Biogen Says Estimated Charge Expected To I...
10/14/2025 20:23:09

- SEC Filing

7-analysts-have-this-to-say-about-biogen
7 Analysts Have This To Say About Biogen
10/10/2025 19:00:46

morgan-stanley-maintains-equal-weight-on-biogen-raises-price-target-to-149
Morgan Stanley Maintains Equal-Weight on B...
10/10/2025 17:36:30

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from ...

Core News & Articles
Biogen And Stoke Announce Phase 3 Zorevune...
10/09/2025 20:32:46

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...

eisai-and-biogen-announce-lecanemab-irmb-subcutaneous-injection-is-now-available-in-us-as-maintenance-dosing-regimen-for-ad-treatment
Eisai And Biogen Announce Lecanemab-Irmb S...
10/06/2025 20:34:02

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nu...

nasdaq-100-top-25000-as-amd-spikes-gold-eyes-4000-whats-moving-markets-monday
Nasdaq 100 Top 25,000 As AMD Spikes, Gold ...
10/06/2025 17:02:18

Tech and AI-related stocks continued to propel Wall Street to new record highs Monday, with Advanced Micro Devices Inc. (NASDAQ...

trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years
Trump-Pfizer Deal Pushes Health Care Stock...
10/01/2025 20:22:35

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION